Effect of ofatumumab versus placebo in relapsing multiple sclerosis patients from Japan and Russia: Phase 2 APOLITOS study

Background: Ofatumumab, the first fully human anti-CD20 monoclonal antibody, has been developed as a treatment for relapsing multiple sclerosis (RMS) which can be self-administered at home. Objective: To investigate the efficacy and safety of ofatumumab in RMS patients from Japan and Russia. Methods...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Multiple sclerosis 2022-07, Vol.28 (8), p.1229-1238
Hauptverfasser:	Kira, Jun-ichi, Nakahara, Jin, Sazonov, Denis V, Kurosawa, Takayoshi, Tsumiyama, Isao, Willi, Roman, Zalesak, Martin, Pingili, Ratnakar, Häring, Dieter A, Ramanathan, Krishnan, Kieseier, Bernd C, Merschhemke, Martin, Su, Wendy, Saida, Takahiko
Format:	Artikel
Sprache:	eng
Schlagworte:	CD20 antigen Clinical trials Gadolinium Lesions Monoclonal antibodies Multiple sclerosis Patients Placebos
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!